EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Time‐Dependent Effect of Prophylactic Trimethoprim‐Sulfamethoxazole on the Incidence of Serious Infections in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Target Trial Emulation Study

Yun Kyu Kim, Jeffrey R Curtis iD, Se Rim Choi, Jina Yeo, Min Jung Kim, Yun Jong Lee iD, Eun Bong Lee iD, Jun Won Park iD

Arthritis & Rheumatology · 2025

DOI: 10.1002/art.43185 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Arthritis & Rheumatology, 2025. Verfasst von Yun Kyu Kim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Antibiotic Prophylaxis, Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAMS NIH HHS, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The objective of this study was to investigate the effect of prophylactic trimethoprim‐sulfamethoxazole (TMP‐SMX) on the incidence of serious infections in patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV).

Methods

This multicenter cohort study was designed to emulate a target trial that studied 296 patients with AAV who were treated with rituximab (RTX) or cyclophosphamide (CYC) as induction therapy. Patients were grouped based on the administration of TMP‐SMX within 14 days following induction therapy (n = 240 and 56 patients in prophylaxis and control groups, respectively) (intention‐to‐treat) and also as a time‐dependent exposure (time‐varying). Inverse probability weighting was applied to minimize the baseline imbalance between the two groups. The primary outcome was one‐year incidence of serious infection.

Results

During the 252.1 person‐years of observation, 77 cases of serious infections were recorded in 65 patients with a fatality rate of 18.5%. Most serious infections (n = 66, 85.7%) occurred within the first 180 days of observation. The prophylaxis group showed a significantly lower incidence of serious infections than the control group (hazard ratio [HR] 0.48 [95% confidence interval (CI) 0.32–0.72]). However, this beneficial effect of TMP‐SMX was only significant during the first 180 days (HR 0.41 [95% CI 0.22–0.76]) and not thereafter (HR 3.67 [95% CI 0.46–29.43]) (interaction P = 0.044). This result was also consistent with the time‐varying analysis result. Based on one case of severe adverse drug reaction related to TMP‐SMX, the number needed to harm was 127.4, whereas the number needed to treat to prevent one serious infection was 8.0.

Conclusion

Prophylactic TMP‐SMX significantly reduced the risk of serious infections in patients with AAV, particularly during the first six months of induction therapy with RTX or CYC. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisAntibiotic ProphylaxisInfectionsTrimethoprim, Sulfamethoxazole Drug CombinationAdultAgedFemaleHumansMaleMiddle AgedCohort StudiesCyclophosphamideImmunosuppressive AgentsIncidenceRituximabTime Factors

Substanzen

Anti-Bacterial AgentsCyclophosphamideImmunosuppressive AgentsRituximabTrimethoprim, Sulfamethoxazole Drug Combination

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama.
  • Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea.
  • Division of Rheumatology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Republic of Korea.
  • Division of Rheumatology, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University, Boramae Medical Center, Seoul, Republic of Korea.
  • Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, and Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital,…

ORCID-Profile: Jeffrey R Curtis, Yun Jong Lee, Eun Bong Lee, Jun Won Park

Förderung

  • NIAMS NIH HHS
  • National Research Foundation of Korea

Zitieren

APA

Kim, Y. K., Curtis, J. R., Choi, S. R., Yeo, J., Kim, M. J., Lee, Y. J., Lee, E. B., & Park, J. W. (2025). Time‐Dependent Effect of Prophylactic Trimethoprim‐Sulfamethoxazole on the Incidence of Serious Infections in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Target Trial Emulation Study. Arthritis & Rheumatology. https://doi.org/10.1002/art.43185

Vancouver

Kim YK, Curtis JR, Choi SR, Yeo J, Kim MJ, Lee YJ, et al. Time‐Dependent Effect of Prophylactic Trimethoprim‐Sulfamethoxazole on the Incidence of Serious Infections in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Target Trial Emulation Study. Arthritis & Rheumatology. 2025. doi:10.1002/art.43185

BibTeX
@article{Kim2025,
  author = {Kim, Yun Kyu and Curtis, Jeffrey R and Choi, Se Rim and Yeo, Jina and Kim, Min Jung and Lee, Yun Jong and Lee, Eun Bong and Park, Jun Won},
  title = {Time‐Dependent Effect of Prophylactic Trimethoprim‐Sulfamethoxazole on the Incidence of Serious Infections in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Target Trial Emulation Study},
  journal = {Arthritis & Rheumatology},
  year = {2025},
  doi = {10.1002/art.43185}
}
Kostenlos starten →